Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.
Topics covered in this episode include:
• Mike Ramirez: Discussion of results for AMG 510 in colorectal cancer, as well as updates in first-line non-small cell lung cancer for Tecentriq, Opdivo, and Tagrisso (1:17)
• Zach McLellan: PARP inhibitors dual in ovarian cancer, including updates on Zejula, Lynparza, and veliparib (17:41)
• David Dahan: Phase II results for Debio 1143 combined with chemo-radiotherapy for patients with head and neck cancer and for tucatinib combined with Herceptin for patients with HER2+ colorectal cancer (27:47)
• Tara Hansen: Overview on Keytruda in triple-negative breast cancer, combination regimens in hepatocellular carcinoma, and new mechanism of action drugs in renal cell carcinoma (36:00)
Purchase Full Post-Esmo Report